Ozoralizumab
Humanized | |
|---|---|
| Clinical data | |
| Trade names | Nanozora |
| ATC code |
|
| Legal status | |
| Legal status |
|
| Identifiers | |
| CAS Number | |
| ChemSpider |
|
| UNII | |
| KEGG | |
| Chemical and physical data | |
| Formula | C1682H2608N472O538S12 |
| Molar mass | 38434.85 g·mol−1 |
  (what is this?) (verify) | |
Ozoralizumab (trade name Nanozora) is a trivalent anti-tumour necrosis factor alpha (TNFα) nanobody designed for the treatment of inflammatory diseases.[1]
Ozoralizumab was developed by Pfizer Inc, and now belongs to Ablynx NV. Ablynx has licensed the rights to the antibody in China to Eddingpharm. In 2022, ozoralizumab was approved in Japan for the treatment of rheumatoid arthritis.[2]
References
- PMID 22155554.
- ^ "Notification of Approval to Manufacture and Market Nanozora® 30mg Syringes for S.C. Injection, a Therapy for Rheumatoid Arthritis, in Japan Japan's First NANOBODY® Therapeutic" (Press release). Taisho Pharmaceutical Holdings. September 26, 2022.
 | This monoclonal antibody–related article is a stub. You can help Wikipedia by expanding it. |